irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: Immune-related RECIST (irRECIST) were designed to capture atypical responses seen with immunotherapy. We hypothesized that, in patients with metastatic clear cell renal cell carcinoma (mccRCC), candidate biomarkers for nivolumab response would show improved association with clinical endpoints capturing atypical responders (irRECIST) compared with standard clinical endpoints (RECISTv1.1). Experimental Design: Endpoints based on RECISTv1.1 [objective response rate (ORR)/progression-free survival (PFS)] or irRECIST [immune-related ORR (irORR)/immune-related PFS (irPFS)] were compared in patients enrolled in the CheckMate-010 trial. Pretreatment tumors were analyzed by PD-L1 and PD-L2 IHC, and by multiplex immunofluorescence for CD8, PD-1, TIM-3, and LAG-3. T-cell activation signatures were assessed by RNA sequencing. Results: Median irPFS was significantly longer than median PFS. irORR was not significantly different from ORR, but immune-related progressive disease (irPD) rate was significantly lower than progressive disease (PD) rate. Tumor cell (TC) PD-L1 expression was not associated with PFS or ORR, but patients with TC PD-L1 ≥1% had longer median irPFS and higher irORR. High percentage of CD8+ tumor-infiltrating cells (TIC) that are PD-1+TIM-3−LAG-3− (% CD8+PD-1+TIM-3−LAG-3− TIC) correlated with high levels of T-cell activation and was associated with longer median irPFS and higher irORR. Notably, combination of TC PD-L1 expression with % CD8+PD-1+TIM-3−LAG-3− TIC identified three groups of patients for which irPFS and irORR were significantly different. Conclusions: Atypical responders to nivolumab were identified in the CheckMate-010 trial. We observed improved association of candidate biomarkers for nivolumab response with endpoints defined by irRECIST compared with RECISTv1.1. TC PD-L1 expression in combination with PD-1 expression on CD8+ TIC may predict outcome on nivolumab in mccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 5×
“The phenotyping step, based on machine-learning recognition algorithm, was performed by developing three algorithms recognizing: (1) cells monostained for CD8 or costained for CD8 andPD-1, (2) cellsmonostained for CD8or costained for CD8 and TIM-3, and (3) cells monostained for CD8 or costained for CD8 and LAG-3 (Supp…”
BackgroundMethodResultSelf-citationMolecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · cited 2×
“Expression of PD-1, TIM-3, and LAG-3 on CD8þ TIC and their association with clinical outcomes Human tumors have been shown to contain severely exhausted T cells expressing multiple immune checkpoints, and it has been proposed that these cells mediate resistance to PD-1 blockade (34, 35).”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 2×
“3) and interrogated three gene expression signatures associated with T cell activation: the CYT signature, the Teff signature, and the IFN-γ responsive gene signature (27-29).”
BackgroundMethodSelf-citationIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Self-citationLag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096 · cited 1×
“PD-1 with TIM-3 or LAG-3 induces synergistic reduction of tumor growth (35, 39, 40).”
BackgroundMcDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Self-citationHodi, F. S., Ballinger, M., Lyons, B., Soria, J.-C., Nishino, M., Tabernero, J., Powles, T., Smith, D., Hoos, A., McKenna, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.1644 · Cited by 366
Self-citationNishino, M., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-17 · Cited by 95
Cited by
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Braun, D. A., Street, K., Burke, K. P., Cookmeyer, D. L., Denize, T., Pedersen, C. B., Gohil, S. H., Schindler, N., Pomerance, L., Hirsch, L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.02.013 · Cited by 504
Self-citationBeyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Self-citationLigon, J. A., Choi, W., Cojocaru, G., Fu, W., Hsiue, E. H.-C., Oke, T. F., Siegel, N., Fong, M. H., Ladle, B., Pratilas, C. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001772 · Cited by 124
Metadata
- Authors
- Pignon, J.-C., Jegede, O., Shukla, S. A., Braun, D. A., Horak, C. E., Wind-Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., Novak, J. S., Mahoney, K. M., Freeman, G. J., Sharpe, A. H., Hodi, F. S., Motzer, R. J., Choueiri, T. K., Wu, C. J., Atkins, M. B., McDermott, D. F., & Signoretti, S.
- Venue
- Clinical Cancer Research
- Published
- 2019-04-01
- Volume
- 25
- Issue
- 7
- Pages
- 2174-2184
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2913044136
- Cited by
- 113
- References
- 9
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3206
- The paper
- Pignon, J.-C., Jegede, O., Shukla, S. A., Braun, D. A., Horak, C. E., Wind-Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., Novak, J. S., Mahoney, K. M., Freeman, G. J., Sharpe, A. H., Hodi, F. S., Motzer, R. J., Choueiri, T. K., Wu, C. J., Atkins, M. B., . . . Signoretti, S. (2019). irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3206
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.